Exhibit 99.1 TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC) Could Represent an Important New Innovation for Optimizing Immunosuppressive Therapy in Lung Transplant Recipients Raised $6.0 Million to Support Continued Advancement of TFF TAC into Potentially Registrational Testing Company expects to receive feedback from FDA in Second Quarter Regarding TFF TAC ...